ATM serine/threonine kinaseGenealiases: AT1 · ATA · ATC · ATD · ATDC · ATE
Q-omics provides the consensus-scored ATM profile across patient tissues and cancer cell-line models. ATM expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ATM is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, ATM RNA expression shows 21,247 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight HNSC, KIRC, and KIRP as cancer lineages where ATM shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATM — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATM survival associations across molecular data types. ATM RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATM RNA expression–survival associations across cancer types. High ATM expression shows unfavorable associations in UVM, BLCA and ACC, but favorable associations in HNSC, KIRC and UCS. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ATM RNA expression.
This table summarizes ATM tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ATM. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATM shows lower tumor expression in THCA and UCEC and higher tumor expression in KIRC, HNSC, LIHC and CHOL. The KIRC box plot shows higher ATM RNA expression in tumor versus normal tissue (log2 FC = +0.861, t-test p < 0.001).
This table shows molecular features associated with ATM in patient tissues and cancer cell lines. In patient samples, ATM shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ATM RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and KIDNEY.
